Newsletter Series Chair Mark G. Kris, MD Chief, Thoracic Oncology Service William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Cancer Center New York, NY Issue Author Alice Shaw, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, MA CCME Reviewer Amit K. Verma, MBBS Associate Professor of Medicine Albert Einstein College of Medicine Jack and Pearl Resnick Campus Bronx, NY
0.5 credit hour
Approximately 87% of lung cancer cases in the United States are classified as non-small cell lung cancer (NSCLC), and most cases are diagnosed at an advanced stage with poor overall survival. Major steps in the molecular era of lung cancer treatment are being made as clinicians not only rely on histologic classification of lung cancer to guide therapy, but also define lung cancer tumor types based on specific molecular profiles. The use of molecularly targeted therapies represents a significant advance in the treatment of NSCLC.
The gap between optimal management of advanced NSCLC and current clinical practice is widening as many oncologists remain unaware of how best to apply new and emerging clinical evidence into their clinical practice. Oncologists and other cancer professionals have an opportunity to prolong life and improve the quality of life in selected patients with advanced NSCLC by more thoroughly defining molecular subsets of advanced NSCLC and more fully integrating the use of targeted therapies into treatment regimens.
This first issue of the NSCLC iNewsletter Series focuses on the key factors related to testing and treating patients for ALK-positive lung cancer.
. Target Audience
Oncologists, nurse practitioners, physician assistants, nurses, and other health care professionals interested or involved in the treatment of NSCLC.
Upon completion of this educational activity, the participant should be able to:
Identify patients with NSCLC who may benefit from targeted therapy with an ALK inhibitor.
Develop personalized treatment regimens for patients with NSCLC who are ALK positive.
The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
Dr. Kris discloses that he is a consultant to and has received grant funding from Pfizer and Boehringer Ingelheim; and received other honoraria from Roche China.
Dr. Shaw discloses she has been a consultant to Pfizer, Ariad, and Chugai; and has received research funding from Chugai, Novartis, and AstraZeneca.
Albert Einstein College of Medicine:
The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with commercial interests, other than the following:
Steven Jay Feld, or a member of his household owns securities in: Bioheart, Inc., Chelsea Therapeutics, Inc. and Pharmacopeia, Inc.
Amit Verma, MD discloses that he received research support from GSK and is on speakers bureau for Celgene.
Dr. Thier has no relevant financial conflicts to disclose.
Dr. Paczolt has no relevant financial conflicts to disclose.
ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
In order to receive your CME credit, participants will need to review the materials, answer the questions and achieve a score of at least 60% on the post-test.
If you have any questions relating to the accreditation of this activity, please contact:
Center for Continuing Medical Education
Bronx, NY 10467
Commercial Support Statements
This activity was supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
This activity was supported by an independent educational grant from Astellas Pharma Global Development, Inc.
Minimum Hardware/Software Requirements:
Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7. Or, Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers • High-speed internet connection
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page.
The activity will take approximately 30 minutes to complete.
After the activity has finished, it will take you directly to the post-program survey, post-test, and evaluation
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
©2012, Albert Einstein College of Medicine of Yeshiva University and MCM Education. All rights reserved. This publication is designed to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the contents may be reproduced in any form without prior written permission from Albert Einstein College of Medicine and the publisher. The opinions expressed in this newsletter series are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, or Astellas Pharma Global Development, Inc. Any medications or other diagnostic or treatment procedures discussed by the faculty should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.